Submitted by Anonymous (not verified) on 29 November 2023 - 16:01
Human medicines European public assessment report (EPAR): Enhertu, trastuzumab deruxtecan, Breast Neoplasms, Date of authorisation: 18/01/2021, Revision: 13, Status: Authorised
Source: